Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EWWS | ISIN: CA27966L3065 | Ticker-Symbol: RBT
Tradegate
06.06.25 | 17:18
1,700 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EDESA BIOTECH INC Chart 1 Jahr
5-Tage-Chart
EDESA BIOTECH INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,6501,70017:20

Aktuelle News zur EDESA BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
EDESA BIOTECH Aktie jetzt für 0€ handeln
28.05.Edesa Biotech, Inc. - S-8, Securities to be offered to employees in employee benefit plans5
28.05.Edesa Biotech, Inc. - 8-K, Current Report11
14.05.Edesa Biotech, Inc. - 10-Q, Quarterly Report1
14.05.Edesa Biotech, Inc. - 8-K, Current Report1
14.05.Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results132TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases...
► Artikel lesen
05.04.Edesa Biotech names Peter Weiler as new CFO1
04.04.Edesa Biotech announces CFO transition1
04.04.Edesa Biotech, Inc. - 8-K, Current Report2
04.04.Edesa Biotech, Inc.: Edesa Biotech Announces Chief Financial Officer Transition134TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases...
► Artikel lesen
04.03.Edesa Biotech files to sell 7.81M common shares for holders4
14.02.Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal 1st Quarter 2025 Results170TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases...
► Artikel lesen
14.02.Edesa Biotech, Inc. - 10-Q, Quarterly Report1
13.02.Edesa Biotech announces $15 million private placement11
13.02.Pre-market Movers: Edesa Biotech, The Trade Desk, Aspen Aerogels, AppLovin, Dutch Bros.553OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Edesa Biotech, Inc. (EDSA) is up over 74% at $3.25. AppLovin...
► Artikel lesen
13.02.Edesa Biotech shares jump on $15M private placement31
13.02.Edesa Biotech, Inc.: Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules11
13.02.Edesa Biotech, Inc. - 8-K, Current Report2
20.12.24Edesa Biotech, Inc. - 10-K/A, Annual Report2
13.12.24Edesa Biotech GAAP EPS of -$1.93 beats by $0.223
13.12.24Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal Year 2024 Results162TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1